Physiologic characterisation of glioblastoma multiforme using MRI-based hypoxia mapping, chemical shift imaging, perfusion and diffusion maps

PURPOSE A multiparametric, physiologic MRI approach was considered to more completely characterise biopsy-confirmed glioblastoma multiforme (GBM). Chemical shift imaging (CSI) supplied biochemical information in metabolite ratios, while perfusion images provided data on presumed vascularity from regional cerebral blood volume (rCBV) and permeability maps. Diffusion-weighted images were reduced to apparent diffusion coefficient (ADC) maps to evaluate cellularity, and blood oxygen level-dependent imaging was used to create maps of putative hypoxic regions. METHODS Six post-treatment GBM patients were scanned at 3-month intervals until recurrence was suggested by conventional MRI parameters, yielding 20 scans for consideration. The percentage of extreme values in each technique that overlapped with other parameters was measured and compared across hemispheres to assess utility. RESULTS We found significantly better performance in selecting the diseased hemisphere for overall percent overlap when compared to voxel counts from individual thresholded parameter maps. Parameters were selected on the basis of highest overlap, and corresponding composite overlap maps show increased specificity to likely recurrent regions by reducing the number of falsely positive voxels, and offer insight into relationships between various parameters. CONCLUSION In a pilot group of patients, percent overlap appears to be sensitive to recurrent disease. When used to combine multiple parameters, voxels containing overlap can specifically target probable recurrent areas.

[1]  J R Griffiths,et al.  The response of human tumors to carbogen breathing, monitored by Gradient-Recalled Echo Magnetic Resonance Imaging. , 1997, International journal of radiation oncology, biology, physics.

[2]  Glyn Johnson,et al.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.

[3]  Ajay Singh,et al.  Brain lesions with elevated lactic acid peaks on magnetic resonance spectroscopy. , 2004, Current problems in diagnostic radiology.

[4]  F. Howe,et al.  The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging. , 1997, British Journal of Cancer.

[5]  A. Jackson,et al.  Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors , 2000, Journal of magnetic resonance imaging : JMRI.

[6]  Sylvie Grand,et al.  A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images , 2000, Nature Medicine.

[7]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[8]  R W Cox,et al.  AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. , 1996, Computers and biomedical research, an international journal.

[9]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[10]  K. Wallner,et al.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. , 1989, International journal of radiation oncology, biology, physics.

[11]  J. Griffiths,et al.  Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo. , 2004, Neoplasia.

[12]  Lawrence O. Hall,et al.  Automatic tumor segmentation using knowledge-based techniques , 1998, IEEE Transactions on Medical Imaging.

[13]  R. Henry,et al.  Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. , 2000, AJNR. American journal of neuroradiology.

[14]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[15]  M. Kitajima,et al.  Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI , 2002, Neuroradiology.

[16]  T. Cloughesy,et al.  Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma , 1999, Magnetic resonance in medicine.

[17]  Karl-Josef Langen,et al.  Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas? , 2004, Journal of magnetic resonance imaging : JMRI.

[18]  J. Knisely,et al.  Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  P Jack Hoopes,et al.  Changes in oxygenation of intracranial tumors with carbogen: A BOLD MRI and EPR oximetry study , 2002, Journal of magnetic resonance imaging : JMRI.

[20]  A. Sorensen,et al.  Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. , 2002, AJR. American journal of roentgenology.

[21]  Hamid Soltanian-Zadeh,et al.  MRI tissue characterization of experimental cerebral ischemia in rat , 2003, Journal of magnetic resonance imaging : JMRI.

[22]  Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. , 1997 .

[23]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[24]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[25]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.